ZFGN Zafgen, Inc.

3.85
-0.12  -3%
Previous Close 3.97
Open 3.98
Price To book 0.98
Market Cap 105.38M
Shares 27,372,000
Volume 213,620
Short Ratio 3.62
Av. Daily Volume 208,395

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation due 2H 2017. Phase 1 positive safety data released May 4, 2017.
ZGN-1061
Diabetes
Announced July 2016 suspension of development of Beloranib
Beloranib
Severe obesity
Announced July 2016 suspension of development of Beloranib
Beloranib
Prader-Willi Syndrome (PWS)
Announced July 2016 suspension of development of Beloranib
Beloranib
Severe obesity